Welcome to our dedicated page for Ventyx Biosciences SEC filings (Ticker: VTYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ventyx Biosciences, Inc. (VTYX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated summaries. Ventyx is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market under the symbol VTYX, as noted in its Form 8-K filings, and is therefore required to file periodic and current reports under the Securities Exchange Act of 1934.
Through this page, readers can review Ventyx’s Forms 10-K and 10-Q, which describe its business focus on oral small-molecule therapies for autoimmune, inflammatory, cardiovascular and neurodegenerative diseases, and provide details on its NLRP3 inhibitor programs (VTX2735 and VTX3232) and inflammatory bowel disease portfolio (tamuzimod/VTX002 and VTX958). Current reports on Form 8-K referenced in the input include announcements of quarterly financial results and top-line Phase 2 clinical data, such as the October 22, 2025 filing describing VTX3232 Phase 2 results in obesity and cardiovascular risk factors and the November 6, 2025 filing furnishing third-quarter financial results.
AI-powered tools on Stock Titan can help explain the key points in lengthy filings, such as risk factor sections, clinical development updates, and discussions of cash runway and operating plans. Users can also monitor 8-K filings related to material events, including the joint press release with Eli Lilly and Company announcing a definitive agreement for Lilly to acquire Ventyx in an all-cash transaction, subject to stockholder and regulatory approvals.
In addition, this page can surface Forms 3, 4 and 5 that report transactions in VTYX securities by directors and officers, as referenced generally in Ventyx’s proxy and ownership discussions. Real-time updates from EDGAR combined with AI summaries allow investors to quickly understand how new filings may relate to Ventyx’s clinical-stage pipeline, financial condition and the progress of its proposed acquisition by Eli Lilly and Company.
Ventyx Biosciences, Inc. agreed to be acquired by Eli Lilly and Company in an all-cash merger, under which each share of common stock will be converted into the right to receive $14.00 per share in cash, and each share of preferred stock will be converted into the right to receive $1,400.00 per share in cash, in each case less applicable tax withholding. The transaction will be completed through a merger of a Lilly subsidiary into Ventyx, with Ventyx surviving as a wholly owned subsidiary of Lilly, subject to customary closing conditions.
The deal requires approval by Ventyx stockholders at a special meeting and receipt of required regulatory clearances, and it is subject to an outside date of October 7, 2026, after which either party can generally terminate if closing has not occurred. A voting and support agreement covers holders controlling about 10% of the common stock as of January 5, 2026, committing them to vote in favor of the merger, and a termination fee of $44,000,000 may be payable by Ventyx to Lilly if the agreement is ended under specified circumstances, including accepting a superior proposal.
Ventyx Biosciences, Inc. (VTYX) filed a Form 4 reporting an open market-equivalent share purchase by its Chief Medical Officer. The reporting person acquired 3,000 shares of Ventyx common stock on November 17, 2025 through the company’s 2021 Employee Stock Purchase Plan. The shares were bought at a price of $1.03 per share, calculated as 85% of the closing price on May 15, 2025, in line with the ESPP terms.
Following this transaction, the reporting person beneficially owns 6,000 shares of Ventyx common stock, held directly. The filing notes that the transaction is exempt under Rule 16b-3(c) and that it was reported on a voluntary basis in connection with the ESPP purchase period running from May 15, 2025 through November 14, 2025.
Ventyx Biosciences, Inc. (VTYX) reported an insider stock purchase by its Senior VP of Finance, who filed individually. On November 17, 2025, the officer acquired 1,767 shares of common stock at a purchase price of $1.03 per share through the company’s 2021 Employee Stock Purchase Plan (ESPP). After this transaction, the officer beneficially owns 5,313 shares of Ventyx common stock in direct ownership.
The filing notes that the purchase relates to the ESPP purchase period running from May 15, 2025 through November 14, 2025 and that the transaction is exempt under Rule 16b-3(c). The shares were bought at 85% of the closing price on May 15, 2025, consistent with the terms of the 2021 ESPP.
Ventyx Biosciences (VTYX) reported Q3 2025 results. The company recorded a net loss of $22.8 million for the quarter and $77.3 million year-to-date. Operating expenses declined to $24.9 million from $38.6 million a year ago, driven by lower research and development spend ($17.7 million vs. $30.6 million) while general and administrative expenses were $7.2 million (vs. $7.9 million). Interest income contributed $2.1 million in the quarter.
Liquidity remained solid with $31.97 million in cash and cash equivalents and $160.67 million in marketable securities as of September 30, 2025. Total assets were $211.5 million and stockholders’ equity was $191.4 million. Shares outstanding were 71,336,958 as of September 30, 2025; 71,358,638 were outstanding as of November 3, 2025. The pipeline update highlights ongoing Phase 2 work for NLRP3 inhibitors (VTX2735 in recurrent pericarditis; VTX3232 in Parkinson’s disease and cardiometabolic risk) and partnering plans for tamuzimod in ulcerative colitis.
Ventyx Biosciences (VTYX) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1 to this Form 8-K and is being furnished, not filed, under the Exchange Act. As furnished information, it is not subject to Section 18 liabilities and will only be incorporated by reference into other filings if expressly stated.
Ventyx Biosciences (VTYX) announced top-line data from its Phase 2 trial of VTX3232, a CNS-penetrant NLRP3 inhibitor, in participants with obesity and cardiovascular risk factors. The company will host a conference call at 4:30pm ET on October 22, 2025 to review the results.
The press release and a topline results presentation are provided as Exhibits 99.1 and 99.2. The information was furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.
Point72 (Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen) reports beneficial ownership of 5,895,069 shares of Ventyx Biosciences common stock, representing 8.3% of the class as of the close of business on June 30, 2025. The filing clarifies that Point72 Asset Management has shared voting and dispositive power over these Shares held by Point72 Associates, that Point72 Capital Advisors is the general partner, and that Mr. Cohen controls both entities. The statement notes the shares were not acquired to change control of the issuer and that Cubist Systematic Strategies, LLC acts as a sub-advisor for a portion of the reported position.